Works Cited

Attention Deficit Hyperactivity Disorder

Course #96214 - $30-

  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.

1. National Institute of Mental Health. Attention-Deficit/Hyperactivity Disorder. Available at https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd. Last accessed September 9, 2024.

2. Centers for Disease Control and Prevention. Attention-Deficit/Hyperactivity Disorder. Data and Statistics About ADHD. Available at https://www.cdc.gov/adhd/data/?CDC_AAref_Val=https://www.cdc.gov/ncbddd/adhd/data.html. Last accessed September 9, 2024.

3. QuickStats: Percentage of children aged 3–17 years who ever received a diagnosis of attention-deficit/hyperactivity disorder, by sex and age group—National Health Interview Survey, United States, 2019. MMWR. 2021;70:1024.

4. Zablotsky B, Alford JM. Racial and Ethnic Differences in the Prevalence of Attention-Deficit/Hyperactivity Disorder and Learning Disabilities Among U.S. children Aged 3–17 Years. Available at https://www.cdc.gov/nchs/products/databriefs/db358.htm. Last accessed 9, 2024.

5. Soreff S. Attention Deficit Hyperactivity Disorder (ADHD): Pathophysiology. Available at https://emedicine.medscape.com/article/289350-overview. Last accessed September 22, 2021.

6. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.

7. Anxiety and Depression Association of America. Adult ADHD. Available at https://adaa.org/understanding-anxiety/related-illnesses/other-related-conditions/adult-adhd. Last accessed September 9, 2024.

8. Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J Atten Disord. 2005;9(2):384-391.

9. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921.

10. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67(4):524-540.

11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text revision. Washington, DC: American Psychiatric Publishing, Inc.; 2022.

12. U.S. Food and Drug Administration. Press Release. FDA Permits Marketing of First Brain Wave Test to Help Assess Children and Teens for ADHD. Available at https://wayback.archive-it.org/7993/20170112223021/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm360811.htm. Last accessed September 22, 2024.

13. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):1-27.

14. Ramsay JR. Psychological assessment of adults with ADHD. In: Barkley RA (ed). Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 4th ed. New York, NY: The Guilford Press; 2015.

15. Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med. 2006;36(2):167-179.

16. Biederman J, Petty CR, Evans M, Small J, Faraone SV. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res. 2010;177(3):299-304.

17. Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol. 2002;111(2):279-289.

18. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry. 1998;155(4):493-498.

19. Barkley RA, Murphy KR, Fischer M. ADHD in Adults: What the Science Says. New York, NY: The Guildford Press; 2008.

20. Kessler RC, Adler LA, Gruber MJ, Sarawate CA, Spencer T, Van Brunt DL. Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members. Int J Methods Psychiatr Res. 2007;16(2):52-65.

21. Ustun B, Adler LA, Rudin C, et al. The World Health Organization Adult Attention-Deficit/Hyperactivity Disorder Self-Report Screening Scale for DSM-5. JAMA Psychiatry. 2017;74(5):520-526.

22. Wender PH. Attention-Deficit Hyperactivity Disorder in Adults. 1st ed. New York, NY: Oxford University Press; 1998.

23. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry. 2004;161(11):1948-1956.

24. Wilens TE, Dodson W. A clinical perspective of attention-deficit/hyperactivity disorder into adulthood. J Clin Psychiatry. 2004;65(10):1301-1313.

25. Van der Kooij MA, Glennon JC. Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. Neurosco Biobehav Rev. 2007;31(4):597-618.

26. Biederman J, Faraone S. Attention-deficit hyperactivity disorder. Lancet. 2005;366(9481):237-248.

27. Nass R, Sidhu R, Ross G. Autism and other developmental disabilities. In: Daroff RB, Jankovic J, Mazziotta J, Pomeroy SL (eds). Bradley's Neurology in Clinical Practice. 7th ed. Philadelphia, PA: Elsevier Saunders; 2016: 1301-1323.

28. Tcheremissine OV, Salazar JO. Pharmacotherapy of adult attention deficit/hyperactivity disorder: review of evidence-based practices and future directions. Expert Opin Pharmacother. 2008;9(8):1299-1310.

29. Canadian Attention Deficit Hyperactivity Resource Alliance. Canadian ADHD Practice Guidelines. 4th ed. Toronto: CADDRA; 2020.

30. National Collaborating Centre for Mental Health. Attention Deficit Hyperactivity Disorder: The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People, and Adults. Leicester: The British Psychological Society and the Royal College of Psychiatrists; 2008.

31. National Institute for Health and Care Excellence. Attention Deficit Hyperactivity Disorder: Diagnosis and Management. Available at https://www.nice.org.uk/guidance/ng87. Last accessed September 9, 2024.

32. Arnold LE. Methylphenidate vs. amphetamine: comparative review. J Atten Disord. 2000;3(4):200-211.

33. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;S2215-S0366(18):30269-30274.

34. Kollins SH. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Curr Med Res Opin. 2008;24(5):1345-1357.

35. LexiDrug. Available at https://online.lexi.com. Last accessed September 22, 2021.

36. Washington N. Treating ADHD: What Are My Options?. Available at https://psychcentral.com/disorders/adhd/treatment-for-attention-deficit-hyperactivity-disorder-adhd. Last accessed September 9, 2024.

37. Swanson J, Greenhill L, Wigal T, et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1304-1313.

38. Kim HW, Kim SO, Shon S, Lee JS, Lee HJ, Choi JH. Effect of methylphenidate on height and weight in Korean children and adolescents with attention-deficit/hyperactivity disorder: a retrospective chart review. J Child Adolesc Psychopharmacol. 2014;24(8):448-453.

39. Moungnoi P, Maipang P. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health. J Med Assoc Thai. 2011;94(Suppl 3):S158-S163.

40. Carson CC 3rd, Mino RD. Priapism associated with trazodone therapy. J Urology. 1988;139(2):369-370.

41. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(18):2407-2423.

42. Perrin JM, Friedman RA, Knilans TK, the Black Box Working Group, the Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122(2):451-453.

43. Feldman H, Crumrine P, Handen BL, Alvin R, Teodori J. Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child. 1989;143(9):1081-1086.

44. Hemmer SA, Pasternak JF, Zecker SG, Trommer BL. Stimulant therapy and seizure risk in children with ADHD. Pediatr Neurol. 2001;24(2):99-102.

45. Aldenkamp AP, Arzimanoglou A, Reijs R, Van Mil S. Optimizing therapy of seizures in children and adolescents with ADHD. Neurology. 2006;67:S49-S51.

46. Santos K, Palmini A, Radziuk AL, et al. The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies. Dev Med Child Neurol. 2013;55(7):654-660.

47. Radziuk AL, Kieling RR, Santos K, Rotert R, Bastos F, Palmini AL. Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies. Epilepsy Behav. 2015;46:215-220.

48. Hesapcioglu ST, Goker Z, Bilginer C, Kandil S. Methylphenidate-induced psychotic symptoms: two case reports. J Med Cases. 2013;4(2):106-108.

49. Bloom AS, Russell LJ, Weisskopf B, Blackerby JL. Methylphenidate-induced delusional disorder in a child with attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1988;27(1):88-89.

50. Palumbo DR, Sallee FR, Pelham WE Jr, Bukstein OG, Daviss WB, McDermott MP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(2):180-188.

51. Waknine Y. FDA Approves Extended-Release Clonidine for Pediatric ADHD. Available at https://www.medscape.com/viewarticle/730140#. Last accessed September 22, 2024.

52. Strange BC. Once-daily treatment of ADHD with guanfacine: patient implications. Neuropsychiatr Dis Treat. 2008;4(3):499-506.

53. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73-e84.

54. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6–12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24(9):755-768.

55. Findling RL, McBurnett K, White C, Youcha S. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014;24(5):245-252.

56. Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13(12):1047-1055.

57. Wolraich ML, Hagan JF, Allan C, et al. AAP Subcommittee on Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528.

58. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001;158(2):282-288.

59. Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921.

60. Casat CD, Pleasants DZ, Schroeder DH, Parler DW. Bupropion in children with attention deficit disorder. Psychopharmacol Bull. 1989;25(2):198-201.

61. Clay TH, Gualtieri CT, Evans RW, Gullion CM. Clinical and neuropsychological effects of the novel antidepressant bupropion. Psychopharmacol Bull. 1988;24(1):143-148.

62. Riggs PD, Leon SL, Mikulich SK, Pottle LC. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorders. J Am Acad Child Adolesc Psychiatry. 1998;37(12):1271-1278.

63. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34(5):649-657.

64. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001;158(2):282-288.

65. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005;57(7):793-801.

66. Reimherr FW, Hedges DW, Strong RE, Marchant BK, Williams ED. Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial. Neuropsychiatr Dis Treat. 2005;1(3):245-251.

67. Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2017;10(10):CD009504.

68. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo-controlled study of desipramine in the treatment of ADD. I: efficacy. J Am Acad Child Adolesc Psychiatry. 1989;28(5):777-784.

69. Wilens TE, Biederman J, Prince J, et al. Six week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153(9):1147-1153.

70. Riddle MA, Nelson JC, Kleinman CS, et al. Sudden death in children receiving Norpramin: a review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry. 1991;30(1):104-108.

71. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry. 1993;32(4):792-797.

72. Waknine Y. Provigil Linked to Risk for Serious Skin Rash, Psychiatric Symptoms. Available at https://www.medscape.com/viewarticle/564854. Last accessed September 22, 2024.

73. Pfiffner LJ, Barkley RA, DuPaul GJ. Treatment of ADHD in school settings. In: Barkley RA (ed). Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 3rd ed. New York, NY: The Guilford Press; 2006.

74. Centers for Disease Control and Prevention. Attention-Deficit/Hyperactivity Disorder (ADHD): Treatment of ADHD. Available at: https://www.cdc.gov/adhd/treatment/index.html Last accessed September 9, 2024.

75. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073-1086.

76. Molina BSG, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484-500.

77. Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007;46(8):989-1002.

78. Abikoff H, Hechtman L, Klein RG, et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004;43(7):802-811.

79. van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM. The adolescent outcome of children with attention deficit hyperactivity disorder treated with methylphenidate or methylphenidate combined with multimodal behavior therapy: results of a naturalistic follow-up study. Clin Psychol Psychother. 2012;19(3):270-278.

80. Safren SA, Otto MW, Sprich S, Winett CL, Wilens TE, Biederman J. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther. 2005;43(7):831-842.

81. Bramham J, Young S, Bickerdike A, Spain D, McCartan D, Xenitidis K. Evaluation of group cognitive behavioral therapy for adults with ADHD. J Atten Disord. 2009;12(5):434-441.

82. U.S. Food and Drug Administration. FDA Permits Marketing of First Medical Device for Treatment of ADHD. Available at https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-medical-device-treatment-adhd. Last accessed September 22, 2024.

83. Masi L, Gignac M. ADHD and comorbid disorders in childhood psychiatric problems, medical problems, learning disorders and developmental coordination disorder. Clin Psychiatry. 2015.

84. CHADD. ADHD and Co-Occurring Conditions. Available at https://chadd.org/about-adhd/co-occuring-conditions/. Last accessed September 22, 2024.

85. DuPaul GJ, Gormley MJ, Laracy SD. Comorbidity of LD and ADHD: implications of DSM-5 for assessment and treatment. J Learn Disabil. 2013;46(1):43-51.

86. Parvaz MA, Kim K, Froudist-Walsh S, Newcorn JH, Ivanov I. Reward-based learning as a function of severity of substance abuse risk in drug-naïve youth with ADHD. J Child Adolesc Psychopharmacol. 2018;28(8):547-553.

87. Masi G, Manfredi A, Nieri G, Muratori P, Pfanner C, Milone A. A naturalistic comparison of methylphenidate and risperidone monotherapy in drug-naïve youth with attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder and aggression. JClin Psychopharmacol. 2017;37(5):590-594.

88. Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with co-morbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915-924.

89. Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L. Bupropion sustained release in adolescents with co-morbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry. 2001;40(3):307-314.

90. Spencer TJ, Abikoff HB, Connor DF, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of oppositional defiant disorder with or without co-morbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin Ther. 2006;28(3):402-418.

91. Biederman J, Spencer TJ, Newcorn JH, et al. Effect of co-morbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology (Berl). 2007;190(1):31-41.

92. Klein RG, Abikoff H, Klass E Ganeles D, Seese LM, Pollack S. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry. 1997;54(12):1073-1080.

93. Garg J, Arun P, Chavan BS. Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. Int J Appl Basic Med Res. 2015;5(2):114-118.

94. Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH Jr. Psychopharmacology and aggression. I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41(3):253-261.

95. Parsley I, Zhang Z, Hausmann M, et al. Effectiveness of stimulant medications on disruptive behavior and mood problems in young children. Clin Psychopharmacol Neurosci. 2020;18(3):402-411.

96. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003;42(8):886-894.

97. Kronenberger WG, Giaugue AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DW. Quetiapine addition in methylphenidate treatment-resistant adolescents with co-morbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17(3):334-347.

98. Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behavior disorders in children and youths. Cochrane Database Syst Rev. 2017;8:CD008559.

99. Barkley RA, Fischer M, Smallish L, Fletcher K. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics. 2003;111(1):97-109.

100. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 2008;165(5):597-603.

101. Kollins SH. ADHD, substance use disorders, and psychostimulant treatment current literature and treatment guideline. J Atten Disord. 2008;12(2):115-125.

102. Miranda A, Colomer C, Berenguer C, Roselio R, Roselio B. Substance use in young adults with ADHD: Comorbidity and symptoms of inattention and hyperactivity/impulsivity. Int J Clin Health Psychol. 2015;16(2):157-165.

103. Wilens TE, Martelon M, Joshi G, et al. Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. J Am Acad Child Adolesc Psychiatry. 2011;50(6):543-553.

104. Wilens TE, Adamson J, Monuteaux MC, et al. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med. 2008;162(10):916-921.

105. Mannuzza S, Klein RG, Truong NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry. 2008;165(5):604-609.

106. Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood: a naturalistic long-term follow-up study. Addict Behav. 2014;39(1):325-328.

107. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111(1):179-185.

108. Molina BSG, Flory K, Hinshaw SP, et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1028-140.

109. Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry. 2013;70(7):740-749.

110. Gürkan K, Bilgic A, Türkoglu S, Kilic BG, Aysev A, Uslu R. Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment. J Psychopharmacol. 2010;24(12):1810-1818.

111. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with co-morbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1119-1127.

112. Abikoff H, McGough J, Vitiello B, et al. Sequential pharmacotherapy for children with co-morbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2005;44(5):418-427.

113. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing co-morbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001;40(2):147-158.

114. Halldorsdottir T, Ollendick TH. Comorbid ADHD: implications for the treatment of anxiety disorders in children and adolescents. Cog Behavior Pract. 2014;21(3):310-322.

115. Findling RL, Short EJ, McNamara NK, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1445-1453.

116. Scheffer RE, Kowatch RA, Carmody T, Rush AJ. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of co-morbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry. 2005;162(1):58-64.

117. Hah M, Chang K. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol. 2005;15(6):996-1004.

118. Pringsheim T, Steeves T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2011;4:CD007990.

119. Cohen SC, Mulqueen JM, Ferracioli-Oda E, et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2015;54(9):723-736.

120. Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018;6:CD007990.

121. Gulisano M, Rizzo R, Cali PV, Curatolo B. Tourette Syndrome and comorbid ADHD: current pharmacological treatment options. Eur J Paediatric Neurol. 2013;17:421-428.

122. Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med. 2008;10(5):111.

123. Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescription medications. J Am Acad Child Adolesc Psychiatry. 2006;45(4):408-414.

124. McCabe SE, Knight JR, Teter CJ, Wechsler H. Nonmedical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction. 2005;100(1):96-106.

125. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental health Services Administration; 2020.

126. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs. 2006;38(1):43-56.

127. Wilens TE. ADHD with substance use disorders. In: Brown TE (ed). ADHD Comorbidities: Handbook for ADHD Complications in Children and Adults. Washington, DC: American Psychiatric Publishing; 2009.

128. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with co-morbid cocaine dependence. Exp Clin Psychopharmacol. 2002;10(3):286-294.

129. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 2006;81(2):137-148.

130. Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 2007;87(1):20-29.

131. Castells X, Cunill R, Péerez-Mañá C, Vidal X, Capella D. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2016;9:CD007380.

132. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry. 2006;163(3):387-395.

133. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol. 1998;6(4):367-374.

134. Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009;23(4):410-418.

135. Eli Lilly and Company. Strattera (Atomoxetine) Prescribing Information. Available at http://pi.lilly.com/us/strattera-pi.pdf. Last accessed September 22, 2021.

136. Shire US, Inc. Adderall XR (Mixed Salts of A Single-Entity Amphetamine Product) Prescribing Information. Available at http://pi.shirecontent.com/PI/PDFs/AdderallXR_USA_ENG.PDF. Last accessed September 22, 2024.

137. Wilens TE, Zusman RM, Hammerness PG, et al. An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension. J Clin Psychiatry. 2006;67(5):696-702.

138. Weisler RH, Biederman J, Spencer TJ, Wilens TE. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 Suppl 20):35-43.

139. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2005;66(2):253-259.

140. Ayonrinde O. Importance of cultural sensitivity in therapeutic transactions: considerations for healthcare providers. Dis Manage Health Outcomes. 2003;11(4):233-248.

141. Hwa-Froelich DA, Westby CE. Considerations when working with interpreters. Commun Disord Q. 2003;24(2):78-85.

142. National Council on Interpreting in Health Care, Inc. National Standards for Healthcare Interpreter Training Programs. Available at https://www.ncihc.org/assets/documents/publications/National_Standards_5-09-11.pdf. Last accessed September 22, 2024.

143. Lynch EW. Developing cross-cultural competence. In: Lynch EW, Hanson MJ (eds). A Guide for Working with Children and their Families: Developing Cross-Cultural Competence. 4th ed. Baltimore, MD: Paul H. Brookes Publishing, Co.; 2011: 41-78.

144. Tribe R. Working with interpreters in mental health. Int J Cult Ment Health. 2009;2(2):92-101.

145. Dysart-Gale D. Clinicians and medical interpreters: negotiating culturally appropriate care for patients with limited English ability. Fam Community Health. 2007;30(3):237-246.

146. Raval H, Smith J. Therapists' experiences of working with language interpreters. Int J Ment Health. 2003;32(2):6-31.

147. Danielson ML, Claussen AH, Bitsko RH, et al. ADHD prevalence among U.S. children and adolescents in 2022: diagnosis, severity, co-occurring disorders, and treatment. J Clin Child Adolesc Psychol. 2024;53:343-360.

148. Coghill D, Banaschewski T, Cortese S, et al. The management of ADHD in children and adolescents: bringing evidence to the clinic: perspectives from the European ADHD Guidelines Group (EAGG). Eur Child Adolesc Psychiatry. 2023;32:1337-1361.

149. Dimitrov LV, Kaminski JW, Holbrook JR, et al. A systematic review and meta-analysis of chemical exposures and attention-deficit, hyperactivity disorder in children. Prev Sci. 2024;25(2):225-248.

150. Cortese S. Pharmacologic treatment of attention deficit-hyperactivity disorder. N Engl J Med. 2020;383:1050-1056.

  • Back to Course Home
  • Participation Instructions
    • Review the course material online or in print.
    • Complete the course evaluation.
    • Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.